Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Neoplasm Metastasis 8Esophageal Neoplasms 8Carcinoma, Hepatocellular 7Melanoma 6Lung Neoplasms 6Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Pathologic Complete Response 2Nasopharyngeal Carcinoma 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Breast Neoplasms, Male 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Pleural Mesothelial Neoplasm 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Immunotherapy × 1 year × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT07135882 2025-08-22

PRIME-Lung

Trans Tasman Radiation Oncology Group

Phase 3 Not yet recruiting
420 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡